September 12, 2026 10:30 AM – 11:30 AM KST (Korean Time) | Seoul, South Korea
Overview:
ADCs and bispecific antibodies are rapidly changing the treatment landscape in thoracic oncology. In NSCLC, several ADCs and bispecific antibodies are already reshaping established treatment paradigms. In SCLC, novel bispecific T-cell engagers and ADCs are driving meaningful advances in a historically limited therapeutic landscape. As these drug classes expand across lines of therapy, clinicians face growing complexity in treatment selection, sequencing, toxicity management, and biomarker-driven decision-making.
The Medical Crossfire® format is uniquely suited to closing these gaps, bringing together leading thoracic oncology experts at the point where practice-changing data emerges. Its structured debate format allows expert disagreement to surface — and be resolved — in real time, giving physicians greater confidence to implement these cutting-edge therapies in their practice.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Identify the molecular targets and mechanisms of action of individual ADCs and bispecific antibodies relevant to the treatment of NSCLC and SCLC
- Evaluate clinical trial data for approved and investigational ADCs and bispecifics in lung cancer
- Develop individualized treatment strategies for patients with lung cancer, incorporating ADCs and bispecifics, accounting for patient-specific factors, biomarker status, and sequencing implications
Target Audience:
This educational activity is directed toward oncologists, NPs/PAs, nurses, pharmacists, and other HCPs involved in the management of lung cancer.
This program was approved by the IASLC 2026 World Conference on Lung Cancer Program and Education Committees as an independent activity held in conjunction with the IASLC 2026 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official
IASLC accredited program.